GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Predictive Oncology Inc (NAS:POAI) » Definitions » Cyclically Adjusted Price-to-FCF

Predictive Oncology (Predictive Oncology) Cyclically Adjusted Price-to-FCF : (As of Jun. 10, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Predictive Oncology Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Predictive Oncology Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Predictive Oncology's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Oncology Cyclically Adjusted Price-to-FCF Chart

Predictive Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Predictive Oncology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Predictive Oncology's Cyclically Adjusted Price-to-FCF

For the Medical Instruments & Supplies subindustry, Predictive Oncology's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Predictive Oncology's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Predictive Oncology's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Predictive Oncology's Cyclically Adjusted Price-to-FCF falls into.



Predictive Oncology Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Predictive Oncology's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Predictive Oncology's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.841/131.7762*131.7762
=-0.841

Current CPI (Mar. 2024) = 131.7762.

Predictive Oncology Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -196.000 100.560 -256.844
201409 -1,230.000 100.428 -1,613.943
201412 -228.000 99.070 -303.271
201503 -13.000 99.621 -17.196
201506 -209.000 100.684 -273.542
201509 -4,439.000 100.392 -5,826.734
201512 -2,887.000 99.792 -3,812.293
201603 -401.750 100.470 -526.932
201606 -92.462 101.688 -119.820
201609 -54.706 101.861 -70.772
201612 -29.913 101.863 -38.697
201703 -36.969 102.862 -47.361
201706 -29.935 103.349 -38.169
201709 -34.774 104.136 -44.004
201712 -40.182 104.011 -50.908
201803 -30.719 105.290 -38.447
201806 -25.661 106.317 -31.806
201809 -15.470 106.507 -19.140
201812 -16.676 105.998 -20.732
201903 -25.975 107.251 -31.915
201906 -6.673 108.070 -8.137
201909 -12.108 108.329 -14.729
201912 -14.995 108.420 -18.225
202003 -12.370 108.902 -14.968
202006 -7.640 108.767 -9.256
202009 -4.459 109.815 -5.351
202012 -2.530 109.897 -3.034
202103 -2.035 111.754 -2.400
202106 -0.948 114.631 -1.090
202109 -0.939 115.734 -1.069
202112 -1.200 117.630 -1.344
202203 -0.964 121.301 -1.047
202206 -0.981 125.017 -1.034
202209 -0.728 125.227 -0.766
202212 -0.838 125.222 -0.882
202303 -0.876 127.348 -0.906
202306 -0.959 128.729 -0.982
202309 -0.771 129.860 -0.782
202312 -0.757 129.419 -0.771
202403 -0.841 131.776 -0.841

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Predictive Oncology  (NAS:POAI) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Predictive Oncology Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Predictive Oncology's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Predictive Oncology (Predictive Oncology) Business Description

Traded in Other Exchanges
N/A
Address
2915 Commers Drive, Suite 900, Eagan, MN, USA, 55121
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.
Executives
Robert L Myers officer: CHIEF FINANCIAL OFFICER 4765 BEACON HILL ROAD, EAGAN MN 55122
Nuzum Charles Lee Sr director 633 1ST STREET WEST, SONOMA CA 95476
Veena Rao director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Matthew Hawryluk director C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
St. Clair Gregory Sr director 1645 WHITLEY DRIVE, HARRISBURG PA 17111
Nancy Chung-welch director P O BOX 1572, PEPPERELL MA 01463
Pamela Bush officer: Chief Business Officer 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Daniel E Handley director 1142 S. DIAMOND BAR BLVD. #464, DIAMOND BAR CA 91765
Raymond F Vennare director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
David Stewart Smith director 151 WASHINGTON STREET, PITTSBURGH PA 15218
J Melville Engle director 1 REMINGTON COURT, NAPA CA 94558
Jenkins Christina Lee Md director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Carl I. Schwartz 10 percent owner 20155 N.E. 38TH COURT, UNIT 3104, AVENTURA FL 33180
Richard L Gabriel director 900 COCOANUT AVENUE, SARASOTA FL 34236
Pamela S Prior director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121